Abstract:BACKGROUND:There are limited nationwide data regarding breast cancer surgery in China. The Chinese Anti-Cancer Association's Committee of Breast Cancer Society and the Chinese Society of Breast Surgeons conducted a nationwide survey to examine the use of and barriers associated with surgical options among patients with breast cancer. METHODS:Surveys were sent via e-mail to the directors of 110 centers that performed at least 200 breast cancer operations in 2017. The electronic questionnaire contained 183 questions and covered six aspects, including demographic information about the hospitals and surgeons, surgical practice, and application of breast reconstruction. RESULTS:The selected hospitals were from 31 provinces or municipalities. The overall proportion of breast-conserving surgery (BCS) was 22%. Local gross domestic product was significantly related to the rate of BCS (p = .046). Sentinel lymph node biopsy was performed routinely in 76% of hospitals. Only 14.5% (16/110) of hospitals used the dual-tracer method, including radioisotopes. For patients with cN0 disease receiving BCS with one or two positive sentinel lymph nodes, 20% (22/110) of hospitals accepted omitting axillary lymph node dissection (ALND). For patients who underwent mastectomy, only 4% (4/110) of hospitals accepted omitting ALND. There was an obvious polarization trend in the proportion of oncoplastic breast-conserving surgery (OPS); 35/110 (32%) performed OPS in fewer than 10% of cases, whereas 36/110 (33%) performed OPS in more than 50% of cases. OPS was more likely to be performed in academic hospitals. Volume displacement was more commonly used than volume replacement (p < .001). Breast reconstruction was routinely performed in 96/110 (87%) of hospitals, 62% of which involved cooperation with the plastic surgery department. Factors influencing breast reconstruction after mastectomy included the establishment of a plastic surgery department, regional economy, and cooperation between the plastic and general surgery departments. Overall, the proportion of breast reconstruction procedures after mastectomy was 10.7%, with 70% being implant-based reconstruction, 17% autologous tissue reconstruction, and 13% a combination. Overall, 22% of the hospitals predominantly performed immediate breast reconstruction. For delayed reconstruction, two-stage implant-based breast reconstruction was the first choice for 46% of centers, whereas 20% of centers chose autologous reconstruction. Among the 96 centers that performed autologous-based reconstruction, 96% performed latissimus dorsi flap reconstruction, 65% performed transverse rectus abdominis musculocutaneous flap reconstruction, and 45% used deep inferior epigastric artery perforator flaps. CONCLUSION:The results are of great value for promoting the implementation of a consensus on diagnostic and treatment standards, development of guidelines for breast cancer, and training of breast specialists. IMPLICATIONS FOR PRACTICE:This study aimed to establish comprehensive baseline data on the status of current breast cancer treatment in China by presenting the statistics on clinical treatments and surgeries, the distribution of clinical stages, and the demographic characteristics of patients. This report is based on a survey conducted by the Chinese Anti-Cancer Association's Committee of Breast Cancer Society and the Chinese Society of Breast Surgeons, which examined the use of breast cancer surgical options in hospitals all over the country and the factors hindering the adoption of procedures and techniques. This study makes a significant contribution to the literature because there are limited nationwide data regarding breast cancer surgery in China.

Current Trends in Breast Cancer Treatment in Chinese and Chinese American Women

The Fluctuating Incidence, Improved Survival of Patients with Breast Cancer, and Disparities by Age, Race, and Socioeconomic Status by Decade, 1981-2010

Trends in Disparities and Transitions of Treatment in Patients with Early Breast Cancer in China and the US, 2011 to 2021.

Breast Cancer Screening Beliefs Among Older Chinese Women in Chicago's Chinatown.

Mammography screening disparities in Asian American women: Findings from the California Health Interview Survey 2015-2016.

Breast Cancer Screening and Early Diagnosis in Chinese Women

Breast Cancer Challenges and Screening in China: Lessons from Current Registry Data and Population Screening Studies

Ethnic disparities in breast cancer: A comprehensive analysis of socio-demographic and clinical characteristics among African American, Hispanic, and Caucasian women.

Perceived Benefits and Barriers of Cervical Cancer Screening Among Chinese American Women

Trends in breast cancer screening during the COVID‐19 pandemic within a universally insured health system in the United States, 2017–2022

Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals.

Determinants of Cancer Screening Disparities Among Asian Americans: A Systematic Review of Public Health Surveys

Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women

Lessons learned from a genetic counseling randomized clinical trial: Implications for recruiting individuals identifying as Asians in research.

Abstract 3474: Racial disparities in receipt of surveillance mammography after breast cancer diagnosis

Differences in Breast Cancer Characteristics and Outcomes Between Caucasian and Chinese Women in the US.

Cancer Screening, Knowledge, and Fatalism Among Chinese, Korean, and South Asian Residents of New York City

Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting

Abstract IA22: Understanding the Unique Experience among Chinese Immigrant Breast Cancer Survivors

Disparities in Breast Cancer Treatment and Reconstruction Among Native Hawaiian and Pacific Islander Women: Systematic Review and Meta‐Analysis

Unraveling the impact of social determinants of health on HER2+ early breast cancer screening and treatment in a county oncology setting in China.